EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial

Mian Xi iD, Zhoutian Yang iD, Li Hu iD, Yizhen Fu iD, Dandan Hu, Zhongguo Zhou, Mengzhong Liu iD, Jing Zhao, Jingxian Shen, Qiaoqiao Li iD, Baoqing Chen iD, Li Xu iD und 4 weitere

Journal of Clinical Oncology · 20.03.2025 · 43 (9) · 1073-1082

DOI: 10.1200/jco-24-01532 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2025. Verfasst von Mian Xi und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Recurrence, Local, Radiofrequency Ablation. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). METHODS In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA. The primary end point was local progression-free survival (LPFS), and secondary end points were progression-free survival (PFS), overall survival (OS), local control rate, and safety. RESULTS Between August 2019 and April 2022, 166 patients were assigned to SBRT (n = 83) and RFA (n = 83) groups. After a median follow-up time of 42.8 and 42.9 months in the SBRT and RFA groups, respectively, SBRT demonstrated a significantly better LPFS than that of RFA (hazard ratio [HR], 0.45 [95% CI, 0.24 to 0.87]; P = .014). The 2-year LPFS rates were 92.7% (95% CI, 87.3 to 98.5) with SBRT and 75.8% (95% CI, 67.2 to 85.7) with RFA. The median PFS time of the SBRT and RFA groups was 37.6 (95% CI, 26.0 to 49.2) and 27.6 (95% CI, 20.3 to 34.8) months, respectively (HR, 0.76 [95% CI, 0.50 to 1.15]; P = .190). Nine patients in the SBRT group and 10 in the RFA group died during the follow-up. The 2-year OS rates were 97.6% (95% CI, 94.3 to 100.0) in the SBRT group and 93.9% (95% CI, 88.9 to 99.2) in the RFA group (HR, 0.91 [95% CI, 0.37 to 2.22]; P = .830). The incidences of both acute and late adverse events were comparable between the groups ( P = .436 and P = .715, respectively). CONCLUSION SBRT achieved better LPFS than that of RFA in patients with single recurrent HCC ≤5 cm, especially in HCC ≤2 cm, whereas PFS, OS, and safety were comparable between the two treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNeoplasm Recurrence, LocalRadiofrequency AblationRadiosurgeryAdultAgedFemaleHumansMaleMiddle AgedProgression-Free Survival

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Nutrition, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Mian Xi, Zhoutian Yang, Li Hu, Yizhen Fu, Mengzhong Liu, Qiaoqiao Li, Baoqing Chen, Li Xu, Aiping Fang, Yaojun Zhang

Zitieren

APA

Xi, M., Yang, Z., Hu, L., Fu, Y., Hu, D., Zhou, Z., Liu, M., Zhao, J., Shen, J., Li, Q., Chen, B., Xu, L., Fang, A., Chen, M., Liu, S., & Zhang, Y. (2025). Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. Journal of Clinical Oncology, 43(9), 1073-1082. https://doi.org/10.1200/jco-24-01532

Vancouver

Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. Journal of Clinical Oncology. 2025;43(9):1073-1082. doi:10.1200/jco-24-01532

BibTeX
@article{Xi2025,
  author = {Xi, Mian and Yang, Zhoutian and Hu, Li and Fu, Yizhen and Hu, Dandan and Zhou, Zhongguo and Liu, Mengzhong and Zhao, Jing and Shen, Jingxian and Li, Qiaoqiao and Chen, Baoqing and Xu, Li and Fang, Aiping and Chen, Minshan and Liu, Shiliang and Zhang, Yaojun},
  title = {Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {9},
  pages = {1073--1082},
  doi = {10.1200/jco-24-01532}
}
Kostenlos starten →